Amgen (AMGN) Sales Grew 10%, but Can Earnings Catch Up to the Price?

Amgen (NASDAQ:AMGN) and AstraZeneca reported Phase 3 results this week for Tezspire in eosinophilic esophagitis, a condition that makes swallowing difficult. The trial met both of its main goals, and the benefit lasted through week 52. Tezspire is approved for severe asthma, so a new use would widen a drug that is already growing fast. […]